Yakes FM - Search Results

1

Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis.

Fu C, Bardhan S, Cetateanu ND, Wamil BD, Wang Y, Yan HP, Shi E, Carter C, Venkov C, Yakes FM, Page DL, Lloyd RS, Mernaugh RL, Hellerqvist CG. Fu C, et al. Among authors: yakes fm. Clin Cancer Res. 2001 Dec;7(12):4182-94. Clin Cancer Res. 2001. PMID: 11751519

2

CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis.

Yakes FM, Wamil BD, Sun F, Yan HP, Carter CE, Hellerqvist CG. Yakes FM, et al. Cancer Res. 2000 Oct 15;60(20):5740-6. Cancer Res. 2000. PMID: 11059768

3

Functional studies on the anti-pathoangiogenic properties of CM101.

Yan HP, Carter CE, Wang EZ, Page DL, Washington K, Wamil BD, Yakes FM, Thurman GB, Hellerqvist CG. Yan HP, et al. Among authors: yakes fm. Angiogenesis. 1998;2(3):219-33. doi: 10.1023/A:1009258801899. Angiogenesis. 1998. PMID: 14517462

4

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Moulder SL, et al. Among authors: yakes fm. Cancer Res. 2001 Dec 15;61(24):8887-95. Cancer Res. 2001. PMID: 11751413

5

ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.

Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL. Lenferink AE, et al. Among authors: yakes fm. Cancer Res. 2001 Sep 1;61(17):6583-91. Cancer Res. 2001. PMID: 11522658

6

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Yakes FM, et al. Cancer Res. 2002 Jul 15;62(14):4132-41. Cancer Res. 2002. PMID: 12124352

7

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.

Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL. Bianco R, et al. Among authors: yakes fm. Oncogene. 2003 May 8;22(18):2812-22. doi: 10.1038/sj.onc.1206388. Oncogene. 2003. PMID: 12743604

8

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.

Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH. Qian F, et al. Among authors: yakes fm. Cancer Res. 2009 Oct 15;69(20):8009-16. doi: 10.1158/0008-5472.CAN-08-4889. Epub 2009 Oct 6. Cancer Res. 2009. PMID: 19808973

9

HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer.

Arteaga CL, Moulder SL, Yakes FM. Arteaga CL, et al. Among authors: yakes fm. Semin Oncol. 2002 Jun;29(3 Suppl 11):4-10. doi: 10.1053/sonc.2002.34047. Semin Oncol. 2002. PMID: 12138392 Review.

10

Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.

Gendreau SB, Ventura R, Keast P, Laird AD, Yakes FM, Zhang W, Bentzien F, Cancilla B, Lutman J, Chu F, Jackman L, Shi Y, Yu P, Wang J, Aftab DT, Jaeger CT, Meyer SM, De Costa A, Engell K, Chen J, Martini JF, Joly AH. Gendreau SB, et al. Among authors: yakes fm. Clin Cancer Res. 2007 Jun 15;13(12):3713-23. doi: 10.1158/1078-0432.CCR-06-2590. Clin Cancer Res. 2007. PMID: 17575237

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Search Page

Filters